title: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
abstract: BACKGROUND
  Risk-reducing salpingo-oophorectomy is often considered by carriers of BRCA mutations who have completed childbearing. However, there are limited data supporting the efficacy of this approach. We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations.
  
  
  METHODS
  All women with BRCA1 or BRCA2 mutations identified during a six-year period were offered enrollment in a prospective follow-up study. A total of 170 women 35 years of age or older who had not undergone bilateral oophorectomy chose to undergo either surveillance for ovarian cancer or risk-reducing salpingo-oophorectomy. Follow-up involved an annual questionnaire, telephone contact, and reviews of medical records. The time to cancer in the two groups was compared by Kaplan-Meier analysis and a Cox proportional-hazards model.
  
  
  RESULTS
  During a mean follow-up of 24.2 months, breast cancer was diagnosed in 3 of the 98 women who chose risk-reducing salpingo-oophorectomy and peritoneal cancer was diagnosed in 1 woman in this group. Among the 72 women who chose surveillance, breast cancer was diagnosed in 8, ovarian cancer in 4, and peritoneal cancer in 1. The time to breast cancer or BRCA-related gynecologic cancer was longer in the salpingo-oophorectomy group, with a hazard ratio for subsequent breast cancer or BRCA-related gynecologic cancer of 0.25 (95 percent confidence interval, 0.08 to 0.74).
  
  
  CONCLUSIONS
  Salpingo-oophorectomy in carriers of BRCA mutations can decrease the risk of breast cancer and BRCA-related gynecologic cancer.
authors.affiliation: Clinical Genetics Service, Memorial Sloan-Kettering Cancer Center, New York 10021, USA.
authors.forename: Noah D
authors.initials: ND
authors.lastname: Kauff
authors.forename: Jaya M
authors.initials: JM
authors.lastname: Satagopan
authors.forename: Mark E
authors.initials: ME
authors.lastname: Robson
authors.forename: Lauren
authors.initials: L
authors.lastname: Scheuer
authors.forename: Martee
authors.initials: M
authors.lastname: Hensley
authors.forename: Clifford A
authors.initials: CA
authors.lastname: Hudis
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Ellis
authors.forename: Jeff
authors.initials: J
authors.lastname: Boyd
authors.forename: Patrick I
authors.initials: PI
authors.lastname: Borgen
authors.forename: Richard R
authors.initials: RR
authors.lastname: Barakat
authors.forename: Larry
authors.initials: L
authors.lastname: Norton
authors.forename: Mercedes
authors.initials: M
authors.lastname: Castiel
authors.forename: Khedoudja
authors.initials: K
authors.lastname: Nafa
authors.forename: Kenneth
authors.initials: K
authors.lastname: Offit
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D018572:Disease-Free Survival; D005185:Fallopian Tube Neoplasms / Q000453:epidemiology / Q000517:prevention & control; D005187:Fallopian Tubes / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D018095:Germ-Line Mutation; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D010052:Ovariectomy; D010534:Peritoneal Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D016016:Proportional Hazards Models; D012306:Risk